Number 678 • March 2017

# Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Actavis Pharma Company that the shortage for Act Clarithromycin XL 500 mg Extended-Release Tablet (DIN 02403196) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **March 23, 2017**.

### **CLARITHROMYCIN**

#### **500 MG ORAL EXTENDED-RELEASE TABLET**

00002403196	ACT CLARITHROMYCIN XL	APH	\$ 1.2572
00002413345	APO-CLARITHROMYCIN XL	APX	\$ 1.2572
00002244756	BIAXIN XL	BGP	\$ 2.5144

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Divalproex 125 mg Enteric-Coated Tablet (DIN 02239698) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **March 30, 2017**.

### **DIVALPROEX SODIUM (VALPROIC ACID EQUIVALENT)**

### 125 MG ORAL ENTERIC-COATED TABLET

00002239698	APO-DIVALPROEX	APX	\$ 0.0724
00002400499	DIVALPROEX	SNS	\$ 0.0724
00002239701	NOVO-DIVALPROEX	TEV	\$ 0.0760
00000596418	EPIVAL	BGP	\$ 0.2932

## When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

**780-498-8370** (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free) **FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit** https://www.ab.bluecross.ca/providers/pharmacy-home.php



